JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 28.14 Billion KRW | 88.11% |
| 2022 | 14.96 Billion KRW | 15.86% |
| 2021 | 12.91 Billion KRW | -25.36% |
| 2020 | 17.3 Billion KRW | -21.14% |
| 2019 | 21.93 Billion KRW | 38.67% |
| 2018 | 15.82 Billion KRW | -5.73% |
| 2017 | 16.78 Billion KRW | 10.69% |
| 2016 | 15.16 Billion KRW | 17.86% |
| 2015 | 12.86 Billion KRW | 37.49% |
| 2014 | 9.35 Billion KRW | 473.1% |
| 2013 | 1.63 Billion KRW | -52.92% |
| 2012 | 3.46 Billion KRW | 30.45% |
| 2011 | 2.65 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 6.65 Billion KRW | 29.69% |
| 2024 Q1 | 5.13 Billion KRW | -49.99% |
| 2023 Q2 | 5.66 Billion KRW | -26.06% |
| 2023 Q3 | 4.55 Billion KRW | -19.6% |
| 2023 Q4 | 10.26 Billion KRW | 125.4% |
| 2023 FY | 28.14 Billion KRW | 88.11% |
| 2023 Q1 | 7.66 Billion KRW | 67.47% |
| 2022 Q4 | 4.57 Billion KRW | 62.1% |
| 2022 Q1 | 4.63 Billion KRW | 165.33% |
| 2022 Q2 | 2.93 Billion KRW | -36.74% |
| 2022 Q3 | 2.82 Billion KRW | -3.73% |
| 2022 FY | 14.96 Billion KRW | 15.86% |
| 2021 Q2 | 1.68 Billion KRW | -69.7% |
| 2021 FY | 12.91 Billion KRW | -25.36% |
| 2021 Q4 | 1.74 Billion KRW | -55.67% |
| 2021 Q1 | 5.54 Billion KRW | 200.06% |
| 2021 Q3 | 3.93 Billion KRW | 134.37% |
| 2020 Q3 | 7.98 Billion KRW | 0.82% |
| 2020 FY | 17.3 Billion KRW | -21.14% |
| 2020 Q4 | -5.54 Billion KRW | -169.44% |
| 2020 Q1 | 6.94 Billion KRW | 35.4% |
| 2020 Q2 | 7.91 Billion KRW | 14.07% |
| 2019 Q3 | 5.1 Billion KRW | -12.76% |
| 2019 FY | 21.93 Billion KRW | 38.67% |
| 2019 Q4 | 5.12 Billion KRW | 0.53% |
| 2019 Q2 | 5.84 Billion KRW | -0.32% |
| 2019 Q1 | 5.86 Billion KRW | 28.78% |
| 2018 Q4 | 4.55 Billion KRW | -12.73% |
| 2018 Q3 | 5.21 Billion KRW | 70.27% |
| 2018 Q1 | 2.98 Billion KRW | -3.69% |
| 2018 FY | 15.82 Billion KRW | -5.73% |
| 2018 Q2 | 3.06 Billion KRW | 2.76% |
| 2017 Q4 | 3.09 Billion KRW | -31.59% |
| 2017 Q3 | 4.52 Billion KRW | 3.08% |
| 2017 FY | 16.78 Billion KRW | 10.69% |
| 2017 Q2 | 4.39 Billion KRW | -7.91% |
| 2017 Q1 | 4.76 Billion KRW | 59.23% |
| 2016 Q2 | 3.78 Billion KRW | -18.04% |
| 2016 Q4 | 2.99 Billion KRW | -20.53% |
| 2016 Q3 | 3.76 Billion KRW | -0.39% |
| 2016 FY | 15.16 Billion KRW | 17.86% |
| 2016 Q1 | 4.61 Billion KRW | 42.07% |
| 2015 Q4 | 3.24 Billion KRW | 14.05% |
| 2015 Q3 | 2.84 Billion KRW | -25.53% |
| 2015 FY | 12.86 Billion KRW | 37.49% |
| 2015 Q2 | 3.82 Billion KRW | 0.0% |
| 2014 FY | 9.35 Billion KRW | 473.1% |
| 2013 FY | 1.63 Billion KRW | -52.92% |
| 2012 FY | 3.46 Billion KRW | 30.45% |
| 2011 FY | 2.65 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 491.928% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 51.467% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 147.232% |
| HANDOK Inc. | -28.79 Billion KRW | 197.731% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 434.443% |
| Yuhan Corporation | 93.5 Billion KRW | 69.903% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -153.037% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 213.429% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 80.754% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -702.141% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1222.878% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 1457.049% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 721.988% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -26.021% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 491.928% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 234.397% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -685.404% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 123.796% |
| JW Holdings Corporation | 19.02 Billion KRW | -47.922% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 135.658% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 86.757% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 23.948% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 149.095% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -359.737% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -1591.812% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -462.346% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 491.928% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 23.864% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 74.759% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 23.948% |
| Yuhan Corporation | 93.5 Billion KRW | 69.903% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 273.196% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 826.194% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -359.927% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 23.948% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -48.864% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 41.685% |
| CKD Bio Corp. | -24.19 Billion KRW | 216.333% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -17.674% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -2.572% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 5.476% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 149.095% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 40.129% |
| Boryung Corporation | 40.2 Billion KRW | 29.995% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 189.832% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1222.878% |